Clinic
Jupiter Medical Center, INC.
Jupiter Medical Center, INC. was paid $4.70M by Medicaid between Jan 2018 and Dec 2024, across 133 billing codes. Its largest line is 99283, emergency room visit (moderate) — 16% of everything it billed.
33Billing provider infoJUPITER MEDICAL CENTER, INC.
JUPITER, FL 33458
JUPITER, FL 33458
33aNPI1295721090assigned 09/27/2005
33bProvider typeRehabilitation Clinic/Center
28Total paid$4.70M
24GClaims155,763
24DCodes billed133
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Rehabilitation Clinic/Center providers in Florida
Rank by total paid#6 of 131
Median peer was paid$28K
This provider vs. median168×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 9,898 | $175K | |
| 2019 | 32,678 | $823K | |
| 2020 | 29,733 | $801K | |
| 2021 | 34,557 | $906K | |
| 2022 | 36,484 | $1.09M | |
| 2023 | 9,836 | $619K | |
| 2024incomplete | 2,577 | $285K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 16% | 9,696 | 9,010 | $729K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 7,418 | 6,494 | $686K |
| J7030 | Infusion, normal saline solution , 1000 cc | 13% | 3,020 | 2,321 | $589K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 12% | 2,400 | 2,276 | $551K |
| J3490 | Unclassified drugs | 9.1% | 2,952 | 1,816 | $426K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.7% | 2,399 | 2,041 | $268K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 4.3% | 1,546 | 1,269 | $200K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.2% | 2,155 | 1,886 | $104K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.1% | 2,378 | 1,976 | $100K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.0% | 1,301 | 1,214 | $95K |
| J7120 | Ringers lactate infusion, up to 1000 cc | 1.9% | 338 | 295 | $91K |
| 80053 | Comprehensive metabolic panel | 1.5% | 10,075 | 7,627 | $71K |
121 more codes
| J7050 | Infusion, normal saline solution, 250 cc | 1.5% | 222 | $70K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.5% | 2,535 | $69K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 1.1% | 240 | $50K |
| 87070 | <1% | 810 | $46K | |
| 87486 | <1% | 888 | $39K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,057 | $37K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,303 | $37K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 725 | $33K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,036 | $30K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 770 | $28K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 731 | $26K |
| G0378 | Hospital observation service, per hour | <1% | 2,074 | $24K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 812 | $24K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,984 | $19K |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,823 | $15K |
| 81001 | <1% | 5,881 | $14K | |
| 84703 | <1% | 1,039 | $14K | |
| 59025 | Fetal non-stress test | <1% | 311 | $14K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 502 | $13K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,426 | $12K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 822 | $12K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 1,346 | $12K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,182 | $10K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 72 | $9K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,757 | $9K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 10,442 | $8K |
| 86900 | <1% | 599 | $8K | |
| 87081 | <1% | 793 | $7K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 265 | $7K |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 60 | $7K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 300 | $6K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,144 | $6K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,507 | $6K |
| 74018 | <1% | 355 | $5K | |
| 87077 | <1% | 733 | $5K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,939 | $4K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,360 | $4K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,497 | $3K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 474 | $3K |
| 85610 | <1% | 2,554 | $3K | |
| Q9951 | Low osmolar contrast material, 400 or greater mg/ml iodine concentration, per ml | <1% | 40 | $3K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 181 | $3K |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 15 | $2K |
| 76641 | <1% | 52 | $2K | |
| 85730 | <1% | 1,875 | $2K | |
| 86140 | <1% | 2,135 | $2K | |
| 84484 | <1% | 2,281 | $2K | |
| 87040 | <1% | 1,775 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,852 | $2K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 150 | $2K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 274 | $2K |
| 85027 | <1% | 1,737 | $2K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 183 | $2K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 69 | $1K |
| 94760 | <1% | 1,126 | $1K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 147 | $1K |
| 82150 | <1% | 922 | $1K | |
| 94664 | <1% | 602 | $984.53 | |
| 83735 | <1% | 1,632 | $970.29 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 731 | $841.73 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 818 | $759.64 |
| A9270 | Non-covered item or service | <1% | 2,526 | $746.66 |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 44 | $736.07 |
| 83690 | <1% | 2,299 | $695.58 | |
| 87581 | <1% | 888 | $603.93 | |
| 87186 | <1% | 536 | $586.44 | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,649 | $529.43 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,717 | $489.01 |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 45 | $470.19 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 39 | $404.64 |
| 84702 | <1% | 132 | $377.25 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 585 | $352.62 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 900 | $300.02 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,210 | $299.27 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,587 | $262.21 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 664 | $205.18 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 749 | $178.12 |
| 80061 | Lipid panel | <1% | 597 | $171.87 |
| 84439 | <1% | 680 | $113.19 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,847 | $102.51 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 48 | $80.48 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 646 | $78.46 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 20 | $74.04 |
| 85380 | <1% | 333 | $63.87 | |
| 85652 | <1% | 706 | $63.24 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 2,256 | $55.46 |
| 86901 | <1% | 402 | $53.94 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 61 | $42.10 |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 16 | $39.96 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 26 | $28.83 |
| 84466 | <1% | 22 | $22.23 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 32 | $16.10 |
| 83880 | <1% | 174 | $13.64 | |
| 86886 | <1% | 329 | $8.58 | |
| 87205 | <1% | 45 | $2.36 | |
| 84550 | 0% | 14 | $0.00 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 224 | $0.00 |
| 83540 | 0% | 87 | $0.00 | |
| 96367 | 0% | 23 | $0.00 | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | 0% | 13 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 13 | $0.00 |
| 84100 | 0% | 13 | $0.00 | |
| 72125 | Computed tomography, cervical spine; without contrast material | 0% | 30 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 291 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 131 | $0.00 |
| 0240U | 0% | 32 | $0.00 | |
| 74019 | 0% | 41 | $0.00 | |
| 96376 | 0% | 30 | $0.00 | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 0% | 14 | $0.00 |
| 88342 | 0% | 59 | $0.00 | |
| 82728 | 0% | 12 | $0.00 | |
| 82607 | 0% | 16 | $0.00 | |
| 87807 | 0% | 60 | $0.00 | |
| 83605 | 0% | 71 | $0.00 | |
| 82077 | 0% | 33 | $0.00 | |
| 86308 | 0% | 13 | $0.00 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 0% | 26 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 15 | $0.00 |
| 83615 | 0% | 13 | $0.00 | |
| 82550 | 0% | 18 | $0.00 | |
| 71275 | Computed tomographic angiography, chest, with contrast material | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCOURIS, JOHN (PRESIDENT/CEO)
| Provider | Location | Paid |
|---|---|---|
| Florida Health Sciences Center INC | Tampa, FL | $53.21M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.